Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of REGN15160 in Healthy Volunteers
NCT05293678Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gorivitug in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events. Started Apr 2022; status: completed.
02
Drugs
gorivitug
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05293678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293678.